NEW DELHI/MUMBAI: The drug regulator has issued a notice to Mumbai-based Glenmark Pharma seeking a clarification against a complaint that the company is selling its recently approved Covid-19 drug Fabiflu at an “unaffordable” price and with “false claims” that it can be effective for patients with co-morbidities.
The notice from the Drugs Controller General of India is based on a complaint from a Member of Parliament.
“It has been mentioned in representation that Glenmark has claimed that this drug is effective in co-morbid conditions like hypertension, diabetes whereas in reality, as per protocol summary, this trial was not designed to assess the Fabiflu in co-morbid conditions. No clinically sufficient data specific to these conditions are available,” the letter from DCGI VG Somani sent to Glenmark on Friday said.